Category Archives: Prescribing Newsletter

HRT Shortages – British Menopause Society Update

The British Menopause Society have published a helpful update on current availability of HRT products in the UK – including the following notes: There have been availability issues with many HRT products. Some of these are related to manufacturing shortages, while others are related to supply issues. The BMS has been reassured that these are temporary shortages which Continue Reading »

Valproate Use in Women & Girls with Childbearing Potential – Pragmatic Guide

Experts from 13 national bodies, including seven Royal Colleges, have joined forces to publish practical guidance to support doctors and other health professionals providing care for women and girls in their reproductive years who may be prescribed valproate. The ‘pan-College’ advice is based on 2018 regulations issued by the Medicines and Healthcare Products Regulatory Authority (MHRA) around the Continue Reading »

Unlicensed Liquid Medicines for Children – use of non-standard strengths

Analysis of prescribing of unlicensed liquid medicines for children across NECS-linked CCGs in the North of England has revealed considerable use of ‘non-standard‘ strengths – i.e. strengths other than those recommended by the Royal College of Paediatrics & Child Health (RCPCH) and the Neonatal & Paediatric Pharmacists Group (NPPG). The table below lists the ten unlicensed liquid medicines most Continue Reading »

Standardised Strengths of Unlicensed Liquid Medicines for Children – RCPCH & NPPG Joint Position Statement

The Royal College of Paediatrics & Child Health (RCPCH) and the Neonatal & Paediatric Pharmacists Group (NPPG) have published a joint position statement on Using standardised strengths of unlicensed liquid medicines in children. The joint statement strongly recommends that when children require unlicensed liquid medications, they should receive the RCPCH and NPPG recommended strength, where one exists. The Continue Reading »